Telix Pharmaceuticals 2019 Investor Introduction

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Telix Pharmaceuticals develops diagnostic and therapeutic radiopharmaceuticals for oncology applications including metastatic prostate cancer, renal cell cancer, and glioblastoma. Founded by experienced nuclear medicine executives, the company has multiple clinical programs from pre-NDA to Phase III stages and partnerships with leading global healthcare companies.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Telix Pharmaceuticals

View all →

Telix Pharmaceuticals 2023 Annual General Meeting

annual_report

14 Pages

Telix Pharmaceuticals 2023 J.P. Morgan Healthcare Conference

conference

Similar investor_presentations from other companies

Browse all →

WSP Global Investor Presentation — August 2020

investor_presentation

24 Pages

WSP Global

Westpac New Zealand Covered Bond Investor Presentation 2021

investor_presentation